Multiple Sclerosis Global Clinical Trials Review, H2, 2016

GlobalData
1031 Pages - GLDATA56845
$2,500.00

Summary

GlobalData's clinical trial report, “Multiple Sclerosis Global Clinical Trials Review, H2, 2016" provides an overview of Multiple Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

Biogen, Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
E. Merck KG
Sanofi
Bayer AG
Pfizer Inc.
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd.
Acorda Therapeutics, Inc.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Multiple Sclerosis Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Multiple Sclerosis 29
Jun 15, 2016: Flex Pharma Initiates Phase 2 Efficacy Study in Multiple Sclerosis 29
Jun 13, 2016: Adamas Announces Positive Results from its Phase 2 Proof-of-Concept Study of ADS-5102 for the Treatment of Walking Impairment in Multiple Sclerosis Patients 29
Jun 09, 2016: Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases 30
Jun 01, 2016: Antisense provides update on ATL1102 clinical trials 31
May 10, 2016: Abide Therapeutics Announces First Subject Dosed In PET Occupancy Study with [18F]ABX-1488, a Proprietary Human Monoacylglycerol Lipase (MGLL)-Specific PET Ligand 31
May 09, 2016: Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016 32
May 09, 2016: Arrien Pharmaceuticals to Initiate the Phase I Clinical trials of Autoimmune Drug 32
Apr 20, 2016: Data Presented at AAN Highlight Impact of ZINBRYTA (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action 32
Apr 18, 2016: TECFIDERA Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness 34
Apr 15, 2016: Sanofi Genzyme to present New Investigational Data on Lemtrada (alemtuzumab) at American Academy of Neurology 36
Apr 15, 2016: Sanofi Genzyme to Present Investigational Data on Aubagio (teriflunomide) at American Academy of Neurology 37
Clinical Trial Profile Snapshots 39
Appendix 1028
Abbreviations 1028
Definitions 1028
Research Methodology 1029
Secondary Research 1029
About GlobalData 1030
Contact Us 1030
Disclaimer 1030
Source 1031

List of Tables
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region, 2016* 6
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 1029

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports